Qué financiamos (solo en inglés)

TrueNTH Testicular Cancer is a website, optimised for mobile devices, that aims to bring resources to men who are facing a diagnosis and early treatment for testicular cancer. We have created a resource that delivers information to men to help them navigate the early stages of treatment along with the functionality to connect with a survivor who has lived through the same experience to facilitate peer support and a capacity to seek advice from experts in the field relating to the Testicular Cancer Journey. 

This project supports the Australian and New Zealand Urogenital and Prostate (ANZUP) Clinical Trials Group to faciltate and provide capacity for accrual to the TIGER trial in Australian research hospitals. The TIGER trial is a very large multinational clinical trial investigating which of the two current and commonly used treatments is more effective in preventing death in men who show a relapse of testicular cancer.

This body of work is an extension to previously funded work that helped us better understand the genetic basis and risk for testicular cancer in the population. Professor Clare Turnbull has created an exceptional portfolio of knowledge in this area and is regarded as a world expert. This particular project will leverage the work already undertaken and extend it to create a deeper knowledge of the biology of testicular cancer.

The Advanced Prostate Cancer Consensus Conference (APCCC), to be held in Basel, Switzerland in June 2019, is a key knowledge translation strategy for the clinical implementation of new treatments and therapies in advanced prostate cancer.

The original IGCCCG prognostic score was published 1997 and is built on clinical variables of men with metastatic germ-cell cancers. The database for this score included 5862 patients treated between 1975 and 1990; there have been no updates since.The study aims at building and validating an updated prognostic score to guide decisions in the first-line treatment of patients with metastatic germ-cell cancer. The updated IGCCCG score shall replace the original IGCCCG score as the new international reference.

This project supports the European Organisation for Research and Treatments in Cancer (EORTC) to provide sponsorship for the TIGER trial in Europe. The TIGER trial is a very large multinational clinical trial investigating which of the two current and commonly used treatments is more effective in preventing death in men who show a relapse of testicular cancer.

The aim of the project is to better understand the biology of relapse in testicular cancer. Research undertaken in this project will help build knowledge around why some men with early stage disease relapse after treatment and others don't.

The aim of the project is to better understand the biology of relapse in testicular cancer. Research undertaken in this project will help build knowledge around why some men with early stage disease relapse after treatment and others don't.

The aim of the project is to better understand the biology of relapse in testicular cancer. Research undertaken in this project will help build knowledge around why some men with early stage disease relapse after treatment and others don't.

The aim of the project is to better understand the biology of relapse in testicular cancer. Research undertaken in this project will help build knowledge around why some men with early stage disease relapse after treatment and others don't.

The aim of the project is to better understand the biology of relapse in testicular cancer. Research undertaken in this project will help build knowledge around why some men with early stage disease relapse after treatment and others don't.

The aim of the project is to better understand the biology of relapse in testicular cancer. Research undertaken in this project will help build knowledge around why some men with early stage disease relapse after treatment and others don't.

By using advanced genetic technologies including Next Generation Sequencing and Array SNP Genotyping, the aim of the project is to discover and better understand genetic factors which are linked to the development of testicular cancer.

To provide high quality, localised care and comprehensive support for men in Wales with prostate, testicular and penile cancer in a mobile setting.

To provide support by nursing specialists to men who are diagnosed with prostate or testicular cancer and to provide them with information using one-on-one counselling and support groups especially for those who may not be able to access information through physical or face-to-face meetings.

To facilitate nationwide community based counselling services, free of charge, offering individual counselling for cancer patients, their family members and significant others.